Multiple sclerosis (MS) is a relentless disease, and one with a rising prevalence. The National Institutes of Health estimates that some 200 cases are diagnosed every week in the U.S. alone. The advent of oral therapies is a hopeful sign in the effort to slow progression of the disease. The approval of three MS drugs so far in 2013 – followed by a pipeline brimming with hundreds of compounds – speaks to the resources the biopharma industry is aiming at the disease. (See BioWorld Insight, Nov. 4, 2013.) Read More
When the abstracts for the upcoming annual meeting of the American Society for Hematology were released last week, results of Geron Corp.’s Imetelstat were the biggest attention-grabber as far as the market was concerned. (See BioWorld Today, Nov. 8, 2013.) Read More
